Terms: = Kidney tumors AND PSA
346 results:
1. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract] [Full Text] [Related]
2. Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker.
Zainodini N; Abolhasani M; Mohsenzadegan M; Farajollahi MM; Rismani E
J Cancer Res Clin Oncol; 2024 Mar; 150(3):165. PubMed ID: 38546751
[TBL] [Abstract] [Full Text] [Related]
3. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
4. Transitioning from Da Vinci Si to Xi: assessing surgical outcomes at a high-volume robotic center.
Bravi CA; Mottaran A; Sarchi L; Piro A; Paciotti M; Nocera L; Piramide F; Balestrazzi E; Peraire M; Farinha R; Sorce G; Collà-Ruvolo C; Rebuffo S; De Backer P; D'Hondt F; De Groote R; De Naeyer G; Mottrie A
World J Urol; 2023 Dec; 41(12):3737-3744. PubMed ID: 37917223
[TBL] [Abstract] [Full Text] [Related]
5. Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification.
Ferro M; Rocco B; Maggi M; Lucarelli G; Falagario UG; Del Giudice F; Crocetto F; Barone B; La Civita E; Lasorsa F; Brescia A; Catellani M; Busetto GM; Tataru OS; Terracciano D
Expert Rev Mol Diagn; 2023; 23(12):1061-1070. PubMed ID: 37897252
[TBL] [Abstract] [Full Text] [Related]
6. Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors.
Falagario UG; Lantz A; Jambor I; Busetto GM; Bettocchi C; Finati M; Ricapito A; Luzzago S; Ferro M; Musi G; Totaro A; Racioppi M; Carbonara U; Checcucci E; Manfredi M; D'Aietti D; Porcaro AB; Nordström T; Björnebo L; Oderda M; Soria F; Taimen P; Aronen HJ; Perez IM; Ettala O; Marchioni M; Simone G; Ferriero M; Brassetti A; Napolitano L; Carmignani L; Signorini C; Conti A; Ludovico G; Scarcia M; Trombetta C; Claps F; Traunero F; Montanari E; Boeri L; Maggi M; Del Giudice F; Bove P; Forte V; Ficarra V; Rossanese M; Mucciardi G; Pagliarulo V; Tafuri A; Mirone V; Schips L; Antonelli A; Gontero P; Cormio L; Sciarra A; Porpiglia F; Bassi P; Ditonno P; Boström PJ; Messina E; Panebianco V; De Cobelli O; Carrieri G;
World J Urol; 2023 Nov; 41(11):2967-2974. PubMed ID: 37787941
[TBL] [Abstract] [Full Text] [Related]
7. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.
Falagario UG; Abbadi A; Remmers S; Björnebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
JAMA Netw Open; 2023 Sep; 6(9):e2332900. PubMed ID: 37695584
[TBL] [Abstract] [Full Text] [Related]
8. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract] [Full Text] [Related]
9. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Michalski JM; Winter KA; Prestidge BR; Sanda MG; Amin M; Bice WS; Gay HA; Ibbott GS; Crook JM; Catton CN; Raben A; Bosch W; Beyer DC; Frank SJ; Papagikos MA; Rosenthal SA; Barthold HJ; Roach M; Moughan J; Sandler HM
J Clin Oncol; 2023 Aug; 41(24):4035-4044. PubMed ID: 37315297
[TBL] [Abstract] [Full Text] [Related]
10. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
[TBL] [Abstract] [Full Text] [Related]
11. Inguinal Lymphadenopathy After Renal Transplantation Leading to the Diagnosis of Prostate Cancer: A Case Report.
Enoki Y; Naraki T; Saita K; Mori T; Mitsuke A; Sakaguchi T; Nishimura H; Tatarano S; Yamada Y; Enokida H
Transplant Proc; 2023 May; 55(4):1092-1094. PubMed ID: 37164802
[TBL] [Abstract] [Full Text] [Related]
12. The "Ins and Outs" of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy.
Eltit F; Robinson N; Yu PLI; Pandey M; Lozada J; Guo Y; Sharma M; Ozturan D; Ganier L; Belanger E; Lack NA; Perrin DM; Cox ME; Goldenberg SL
Adv Exp Med Biol; 2023; 1408():291-308. PubMed ID: 37093434
[TBL] [Abstract] [Full Text] [Related]
13. Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results.
Francolini G; Ganovelli M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L
Clin Exp Metastasis; 2023 Apr; 40(2):197-201. PubMed ID: 37012498
[TBL] [Abstract] [Full Text] [Related]
14. Using Isopsa With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated psa.
Benidir T; Lone Z; Wood A; Abdallah N; Campbell R; Bajic P; Purysko A; Nguyen JK; Kaouk J; Haber GP; Eltemamy M; Stein R; Haywood S; Klein EA; Almassi N; Campbell SC; Abouassaly R; Weight CJ
Urology; 2023 Jun; 176():115-120. PubMed ID: 36965817
[TBL] [Abstract] [Full Text] [Related]
15. Isopsa Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the Isopsa Validation Study.
Scovell JM; Stovsky M; Partin A; Lotan Y; Baniel J; Dineen M; Hafron J; Manickam K; Pliskin M; Wagner M; Kestranek A; Klein EA
Urology; 2023 May; 175():132-136. PubMed ID: 36804443
[TBL] [Abstract] [Full Text] [Related]
16. Active surveillance in renal transplant patients with prostate cancer: a multicentre analysis.
Soeterik TFW; van den Bergh RCN; van Melick HHE; Kelder H; Peretti F; Dariane C; Timsit MO; Branchereau J; Mesnard B; Tilki D; Olsburgh J; Kulkarni M; Kasivisvanathan V; Breda A; Biancone L; Gontero P; Gandaglia G; Marra G;
World J Urol; 2023 Mar; 41(3):725-732. PubMed ID: 36710292
[TBL] [Abstract] [Full Text] [Related]
17. Can We Identify Patients in Danger of Delayed Treatment? Management of COVID-19 Pandemic Backlog in Urology Care in Poland.
Ratajczak JM; Gawrońska A; Fischer M; Hladun T; Marczak M
Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554427
[TBL] [Abstract] [Full Text] [Related]
18. Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-α inhibitors: a nationwide nested case-control analysis.
Kim HW; Kim EH; Lee M; Jung I; Ahn SS
Clin Exp Rheumatol; 2023 Jul; 41(7):1491-1499. PubMed ID: 36533975
[TBL] [Abstract] [Full Text] [Related]
19. When to order genomic tests: development and external validation of a model to predict high-risk prostate cancer at the genotypic level.
Falagario UG; Chakravarty D; Martini A; Shahait M; El-Fahmawi A; Jambor I; Lantz A; Grannas D; Ratnani P; Parekh S; Lundon D; Haines K; Cormio L; Carrieri G; Kyprianou N; Kattan MW; Klein EA; Wiklund P; Lee DI; Tewari A
World J Urol; 2023 Jan; 41(1):85-92. PubMed ID: 36484816
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of plasma atherogenic index in predicting malignancy in the presence of Prostate Imaging-Reporting and Data System 3 (PI-RADS 3) prostate lesions.
Senel S; Ceviz K; Kasap Y; Tastemur S; Olcucuoglu E; Uzun E; Polat ME; Koudonas A; Sarialtin F
Int Urol Nephrol; 2023 Feb; 55(2):255-261. PubMed ID: 36357644
[TBL] [Abstract] [Full Text] [Related]
[Next]
